Tandem high-dose (HD) chemotherapy (CT) with VM-26, ifosfamide (IFM), and carboplatin (CBDCA) with autologous bone marrow transplantation (ABMT) for patients with stage IIIC-IV ovarian cancer (OC)

High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer

“…With other regimens, the initial response rate has been reported to be 55-75%. [5][6][7][8][9][10][11][12][13][14] However, relapse remains a major problem in all of the studies. Long-term disease-free survival is seen in only 5-25% of all patients treated.…”

“…Overall, the results of this study with BUMELTT in patients transplanted with relapsed or persistent disease are similar to the results that have been published for other regimens used to treat relapsed or persistent advanced ovarian cancer. [5][6][7][8][9][10][11][12][13][14] A number of different HDC regimens including BUMELTT can lead initially to high overall CR and PR rates in patients with detectable ovarian cancer. Sixty percent of the patients initially evaluated responded to the BUMELTT regimen.…”

“…[5][6][7][8][9][10][11][12][13][14] Patients treated had usually failed at least two prior regimens and had developed progressive disease either during or within 6 months of achieving a remission with platinum therapy. Although initial response rates of 55-75% have been reported, remission durations were consistently short-lived, usually only 5-7 months.…”